Syndax Pharmaceuticals SNDX Ratios & Valuation
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Operating margin | -102.8%+55.4pp | -158.2%+117pp | -275.1%+159pp | -433.7%+353pp | -786.6%— | |
| Net margin | -111.9%+53.5pp | -165.4%+114pp | -279.3%+149pp | -428.5%+329pp | -757.5%— | |
| Returns | ||||||
| Return on equity | -189.5%-27.7pp | -161.8%-32.5pp | -129.3%-16.1pp | -113.2%-19.5pp | -93.7%-18.0pp | |
| Return on assets | -43.7%+1.8pp | -45.5%+18.2pp | -63.7%-1.3pp | -62.4%-6.5pp | -56%-8.3pp | |
| Return on invested capital | -67.9%-17.6pp | -50.3%+59.3pp | -109.6%-14.0pp | -95.5%-6.9pp | -88.6%-24.9pp | |
| Efficiency | ||||||
| Asset turnover | 0.4×+0.1× | 0.3×0.0× | 0.2×+0.1× | 0.1×+0.1× | 0.1×0.0× | |
| Liquidity | ||||||
| Current ratio | 5.5×+1.1× | 4.4×-0.2× | 4.6×-0.1× | 4.7×-1.1× | 5.8×0.0× | |
| Quick ratio | 5.1×+0.9× | 4.1×-0.3× | 4.4×-0.1× | 4.5×-1.2× | 5.8×-0.1× | |
| Cash ratio | 1.5×+0.4× | 1.1×+0.1× | 1×+0.1× | 1×-0.7× | 1.6×+0.1× | |
| Leverage | ||||||
| Debt-to-equity | 8.4×+3.0× | 5.4×+2.6× | 2.8×+0.7× | 2.1×+0.5× | 1.6×-0.8× | |
| Debt-to-assets | 0.7×+0.1× | 0.7×+0.1× | 0.6×0.0× | 0.6×0.0× | 0.5×-0.4× | |
| Per Share | ||||||
| Book value per share | $0.47-36.8% | $0.75-44.0% | $1.33-26.9% | $1.82-26.9% | $2.50-25.8% | |
| Valuation | ||||||
| Market capitalization | $2.06B+12.8% | $1.83B+37.8% | $1.33B+67.0% | $793.36M-24.9% | $1.06B-6.3% | |
| Enterprise value | $2.28B+11.6% | $2.04B+33.0% | $1.54B+51.2% | $1.02B-18.0% | $1.24B-24.7% | |
| Price / sales | 9.5×-1.1× | 10.6×-1.3× | 11.9×+1.7× | 10.1×-14.0× | 24.2×— | |
| Price / book | 49.5×+21.2× | 28.3×+16.8× | 11.5×+6.4× | 5×+0.1× | 4.9×+1.0× | |
| EV / sales | 10.5×-1.3× | 11.8×-1.9× | 13.8×+0.8× | 13×-15.3× | 28.3×— | |
| Earnings yield | -11.8%+3.8pp | -15.6%+7.9pp | -23.5%+18.7pp | -42.2%-10.9pp | -31.3%-3.1pp |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where do Syndax Pharmaceuticals's ratios come from?
- Every ratio is computed from Syndax Pharmaceuticals's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
